Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 11;9:1001–1020. doi: 10.2147/JPR.S112418

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Ueberall and Mueller-Schwefe. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Change of the LBPIX (mean ±95% CIs) during the course of the 12-week observation with TAP (n=133, dashed line) and OXN (n=128, solid line).

Notes: LBPIX improved significantly for both treatment groups vs baseline (P<0.001 for each), but was significantly superior for OXN vs TAP (P<0.05 from the end of Week 7 until the end of Week 12). Dotted line in the lower part of the graph marks the between group difference.

Abbreviations: VAS₁₀₀, 100 mm visual analog scale (0: no pain, 100: worst pain conceivable); BL, baseline; W1–W12, treatment Weeks 1–12; LBPIX, low back pain intensity index; 95% CIs, 95% confidence intervals; OXN, oxycodone/naloxone; TAP, tapentadol.